盐酸塞利洛尔结构式
|
常用名 | 盐酸塞利洛尔 | 英文名 | Celiprolol HCl |
|---|---|---|---|---|
| CAS号 | 57470-78-7 | 分子量 | 415.955 | |
| 密度 | 1.114g/cm3 | 沸点 | 586.5ºC at 760 mmHg | |
| 分子式 | C20H34ClN3O4 | 熔点 | 197-200ºC (dec.) | |
| MSDS | N/A | 闪点 | 308.5ºC |
盐酸塞利洛尔用途Celiprolol hydrochloride 是一种有效的、选择性和具有口服活性的 β1 肾上腺素受体拮抗剂,具有部分 β2 激动剂活性,因此它是一种选择性肾上腺素受体调节剂 (SAM)。Celiprolol hydrochloride 具有降压和抗心绞痛的活性。 |
| 中文名 | 盐酸塞利洛尔 |
|---|---|
| 英文名 | Celiprolol Hydrochloride |
| 中文别名 | 3-[3-乙酰-4-(3-叔丁胺基)-2-羟基丙氧基]苯基-1,1-二乙基脲盐酸盐 |
| 英文别名 | 更多 |
| 描述 | Celiprolol hydrochloride 是一种有效的、选择性和具有口服活性的 β1 肾上腺素受体拮抗剂,具有部分 β2 激动剂活性,因此它是一种选择性肾上腺素受体调节剂 (SAM)。Celiprolol hydrochloride 具有降压和抗心绞痛的活性。 |
|---|---|
| 相关类别 | |
| 靶点 |
β1-andrenoceptor[1] |
| 体内研究 | 西利普洛尔(5或50 mg/kg；每天p.o.连续12周)在50 mg/kg剂量下具有中度降压作用,并显著减轻SHR肠系膜动脉中层平滑肌肥大[2]。动物模型：雄性自发性高血压大鼠(SHR)和同龄Wistar-Kyoto(WKY)大鼠(8周龄)[2]剂量：5,50mg/kg给药：P.o.每天(饮用水中给药),持续12周。结果：50mg/kg剂量组SHR血压升高明显减轻。对心脏或体重没有显著影响。SHR肠系膜动脉平均中层厚度减小。 |
| 参考文献 |
| 密度 | 1.114g/cm3 |
|---|---|
| 沸点 | 586.5ºC at 760 mmHg |
| 熔点 | 197-200ºC (dec.) |
| 分子式 | C20H34ClN3O4 |
| 分子量 | 415.955 |
| 闪点 | 308.5ºC |
| 精确质量 | 415.223785 |
| PSA | 94.39000 |
| LogP | 4.09720 |
| 外观性状 | 白色结晶固体 |
| 储存条件 | Refrigerator |
|
~80%
盐酸塞利洛尔 57470-78-7 |
| 文献：Ji, Li; Qian, Chao; Chen, Xin-Zhi; Mao, Xiao-Yuan 2011 , vol. 35, # 11 p. 640 - 643,4 |
|
~%
盐酸塞利洛尔 57470-78-7 |
| 文献：, vol. 35, # 11 p. 640 - 643,4 |
|
~%
盐酸塞利洛尔 57470-78-7 |
| 文献：Organic Process Research and Development, , vol. 5, # 2 p. 176 - 178 |
|
~%
盐酸塞利洛尔 57470-78-7 |
| 文献：Organic Process Research and Development, , vol. 5, # 2 p. 176 - 178 |
|
~%
盐酸塞利洛尔 57470-78-7 |
| 文献：Organic Process Research and Development, , vol. 5, # 2 p. 176 - 178 |
|
~%
盐酸塞利洛尔 57470-78-7 |
| 文献：, vol. 35, # 11 p. 640 - 643,4 |
|
~%
盐酸塞利洛尔 57470-78-7 |
| 文献：, vol. 35, # 11 p. 640 - 643,4 |
|
~%
盐酸塞利洛尔 57470-78-7 |
| 文献：, vol. 35, # 11 p. 640 - 643,4 |
|
~%
盐酸塞利洛尔 57470-78-7 |
| 文献：, vol. 35, # 11 p. 640 - 643,4 |
|
Highly sensitive transient isotachophoresis sample stacking coupling with capillary electrophoresis-amperometric detection for analysis of doping substances
Talanta 81(4-5) , 1288-94, (2010) A simple and effective method of capillary electrophoresis-amperometric detection (CE–AD) coupled with transient isotachophoresis (tITP) was developed for the trace determination of doping substances.... |
|
|
Simultaneous separation of eight beta-adrenergic drugs using titanium dioxide nanoparticles as additive in capillary electrophoresis.
Electrophoresis 29(11) , 2321-9, (2008) The analysis is described for separating seven beta-adrenergic blocking agents (atenolol, celiprolol, clorprenaline, fenoterol, metoprolol, propranolol, terbutaline) and clenbuterol (sympathomimetic b... |
|
|
Direct determination of celiprolol in human urine using on-line coupled ITP-CZE method with fiber-based DAD.
Electrophoresis 29(22) , 4561-7, (2008) The present work illustrated possibilities of column-coupling electrophoresis combined with DAD for the direct quantitative determination of trace drug (celiprolol, CEL) in clinical human urine sample... |
| MFCD00941500 |
| 3-{3-Acetyl-4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl}-1,1-diethylurea hydrochloride (1:1) |
| Urea, N'-[3-acetyl-4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]phenyl]-N,N-diethyl-, hydrochloride (1:1) |
| (+)-3-(3-Acetyl-4-(3-(tert-butylamino)-2-hydroxypropoxy)phenyl)-1,1-diethylurea hydrochloride |
| Celiprolol Hydrochloride |
| UNII:G1M3398594 |
| 3-(3-Acetyl-4-{2-hydroxy-3-[(2-methyl-2-propanyl)amino]propoxy}phenyl)-1,1-diethylurea hydrochloride (1:1) |
| EINECS 260-752-2 |
| Celiprolol HCl |
| 3-[3-acetyl-4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl]-1,1-diethylurea,hydrochloride |
查看所有供应商和价格请点击：
